Skip to content
thispeptide

FitRx

FitRx describes online prescribing and ongoing clinician access, but its public semaglutide figure requires a quarterly purchase. A named clinical network helps explain who provides care; the pharmacy assignment remains unclear.

Review by Leah Garner, clinical-evidence editor · Updated October 2026

The short version

Confirm which professional practice will treat you and how it handles reassessment before considering a longer purchase. The current public offer does not establish a flexible monthly treatment bill or an individual pharmacy assignment.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

FDA warning letter on record: Letter 717987 · February 2026

Current public pages use FitRx branding and an Inc. footer, while FDA identifies the recipient as FitRX, LLC doing business as FitRx. Confirm the legal seller on the payment agreement. The current weight-loss page sets a cash-pay compounded semaglutide offer apart from insurance-dependent brand access. The terms describe a tirzepatide program as well. A prescription depends on the treating clinician rather than the platform alone.

What FitRx prescribes, by goal

Weight

  • SemaglutideFDA-approved
    • Injection (compounded)Price not published
    • Injection (brand)Price not published
  • TirzepatideFDA-approved
    • Injection (brand)Price not published

FitRx pairs insurance coordination for brand-name medicines with a compounded semaglutide offer. The distinction matters clinically: branded-drug study results do not establish equivalent outcomes for a particular compounded formulation. Ask the clinician to explain the selected treatment, dose and follow-up criteria.

Who prescribes

A licensed clinician

Bruno Health professional association, Outlast Health and affiliated medical groups appear in FitRx’s terms. That identifies a network rather than the clinician who will assess an individual patient. Request the actual practice and state license, plus the dispensing pharmacy’s identity. The website’s technology operator should not be mistaken for the prescriber.

FitRx describes an eligibility questionnaire followed by review of the submitted responses. Its website also promises continuing provider access and online refill tools. Neither statement establishes a fixed appointment schedule. Consent covers remote care, but ask whether your assessment requires a live encounter and who handles concerns between refills.

Are labs required?

Testing plan and charges unconfirmed

FitRx’s payment policy permits recommended diagnostic testing to create a charge. The current product offer does not identify a standard GLP-1 panel or included testing budget. Obtain the required tests, timing and result-review process before starting.

Ready to start with FitRx?

Prices and plans are set on the seller's own site.

What it claims, and what it cites

FDA sent FitRx a February 2026 warning letter after reviewing its website in December 2025. The agency objected to pictured labels implying that the brand compounded the medicine. It also challenged ingredient comparisons that implied FDA evaluation or approval of compounded products. The letter concerns that dated website review; no FDA closeout was confirmed.

How it bills

The semaglutide card uses a $151 monthly equivalent with a quarterly-purchase condition. Its $25 brand headline assumes insurance coverage. Neither is a complete flexible monthly cash quote. The payment policy distinguishes ordinary membership from named medication-plus-doctor packages. Account instructions describe stopping renewal through Manage Membership. Membership and visit charges are ordinarily nonrefundable, and filled prescriptions cannot normally be returned. Clarify what happens if the clinician changes treatment before all of a longer supply is used.

For and against

  • For: Clinical network identified
  • For: Provider-review pathway described
  • For: Account cancellation instructions published
  • Against: Flexible monthly charge unresolved
  • Against: Individual pharmacy assignment unclear
  • Against: Dated FDA warning without confirmed closeout

The evidence behind what it sells

Right for

Someone comparing the clinical follow-up and refund terms of a quarterly offer before committing.

Look elsewhere if

Someone choosing FitRx on the assumption that its quarterly equivalent can be purchased for one month or that every compound has branded-drug approval.

Other sellers for weight

FitRx

Frequently asked questions

Who provides medical care?
Terms identify Bruno Health professional association, Outlast Health and affiliated practices. Ask which clinician and pharmacy will handle the actual prescription.
Does the headline establish a monthly plan?
No. The $151 semaglutide figure is qualified by a quarterly purchase, and the brand headline depends on insurance.
Was the FDA matter closed?
A closeout was not confirmed. The warning describes historical website representations and should be read with its date and precise scope.

Sources

  • Current services and access claims
  • Insurance-dependent brand offers and quarterly semaglutide headline
  • Platform and independent clinical group terms
  • Membership billing, cancellation and refund policy
  • FDA warning letter 717987
  • Clinical group and telehealth consent

See what FitRx prescribes today

FitRx sets its own prices, plans and the states it serves. Check them before you start.

Written by Leah Garner from FitRx’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.